Author:
Li Wei,He Yufeng,Chen Wei,Man Wenling,Fu Qiang,Tan Hongtong,Guo Huanqing,Zhou Jingnan,Yang Po
Funder
Natural Science Foundation of Heilongjiang Province
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Molecular Biology,Molecular Medicine
Reference39 articles.
1. Elserag HB. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
2. Liu K, Wu X, Zang X, Huang Z, Lin Z, Tan W, et al. TRAF4 regulates migration, invasion and the epithelial-mesenchymal transition via PI3K/AKT signaling in hepatocellular carcinoma. Oncol Res. 2017;25:1329–40.
3. Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, Stanley A, et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen. J Hepatol. 2017;68:S0168827817324297.
4. Zhang B, Zhang X, Zhou T, Liu J. Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. Cancer Biol Ther. 2015;16:215–8.
5. Chan SL, Yeo W, Mo F, Chan AWH, Koh J, Li L, et al. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer. 2017;123:3977–85.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献